Drugs / Futuximab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03549338 | Nov 2018 → Mar 2019 | carcinoma, colorectal cancer | Symphogen A/S | Terminated | No outcome recorded |
| Phase 2 | NCT02083653 | Mar 2014 → Oct 2016 | colorectal cancer | Symphogen A/S | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05223673 | Apr 2022 → Jun 2023 | colorectal cancer | Servier | Terminated | No outcome recorded |
| Phase 3 | NCT03717038 | Feb 2019 → Dec 2023 | colorectal carcinoma | Symphogen A/S | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | futuximab | “Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.” NCT03717038 ↗3“Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.” NCT02083653 ↗ |
| Modality | Monoclonal antibody | “one of two mAb components that constitute Sym004” NCT03549338 ↗ |
| Route | Intravenous | “futuximab/modotuximab will be administered via IV route” NCT05223673 ↗ |
| Target | EGFR | “bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.” NCT03717038 ↗ |